{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-148076","form_type":"8-K","ticker":"INO","cik":"0001055726","company_name":"INOVIO PHARMACEUTICALS, INC.","filed_at":"2024-05-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.068663+00:00","generated_at":"2026-06-01T07:53:12.932447+00:00","sec_items":["5.02","5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Inovio grants performance-based RSUs tied to INO-3107 milestones; stockholders re-elect board","bullets":["CEO Shea receives 33,200 target PSUs; CFO Kies and CSO Humeau each receive 8,900 target PSUs.","Up to 70% of PSUs vest on INO-3107 milestones (FDA approval, launch, market share, sales) by 2025-2027.","Remaining 30% vest on relative TSR vs. Russell 2000 Biotech index June 2024-Dec 2027 (50%-150% of target).","Stockholders ratified Ernst & Young as auditor (11.1M for) and approved non-binding say-on-pay (3.0M for).","All eight director nominees elected with votes ranging 3.1M-3.8M for."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-148076","json":"https://secwatch.observer/filing/0001193125-24-148076.json","markdown":"https://secwatch.observer/filing/0001193125-24-148076.md","text":"https://secwatch.observer/filing/0001193125-24-148076.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1055726/000119312524148076/0001193125-24-148076-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1055726/000119312524148076/d597714d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:53:12.932447+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}